Global Fund Modified Documents

OIG_GFOIG10011AuditKenya_Report_en

Genc Kastrati — Fri, 01 Jun 2012 14:46:35 GMT

Our ref: OGM/GJ/JP 19 April, 2012 MESSAGE FROM THE GENERAL MANAGER AND INSPECTOR GENERAL Audit Reports and Diagnostic Review issued by the Global Fund’s Office of the Inspector General on 20 April 2012 Dear Reader: Today the Global Fund has released three audit reports and one diagnostic review. These audits and review

PSM_ProductsMALARIA_List_en

Genc Kastrati — Fri, 01 Jun 2012 14:35:05 GMT

LIST OF MALARIA PHARMACEUTICAL PRODUCTSclassified according to the Global Fund Quality Assurance Policy Edition: Version 57Date: November 5, 2010 ( Reviewed 31/1/2011)http://www.theglobalfund.org/en/about/procurement/list/Please note that the list is not an exhaustive list. A PR can procure product(s) not listed in the

OIG_GFOIG10014AuditEthiopia_Report_en

Genc Kastrati — Fri, 01 Jun 2012 10:49:04 GMT

PSM_ProductsTB_List_en

Genc Kastrati — Fri, 01 Jun 2012 09:21:09 GMT

Edition: Version 27Important Note: The Interim Exception to the Global Fund Quality Assurance Policy was expired on December 31, 2010.Expert Review Panel (ERP): Expert Review Panel is an independent technical body composed of external technical experts, hosted by WHO Department of Essential Medicines and Pharmaceutical

PSM_ProductsHIVAIDS_List_en

Genc Kastrati — Fri, 01 Jun 2012 09:20:56 GMT

4Ethambutol + Isoniazid + Pyrazinamide + Rifampicin (V)4Isoniazid + Rifampicin (V)75mg + 150mgAtazanavir ( as Sulfate)LIST OF ARV PHARMACEUTICAL PRODUCTSclassified according to the Global Fund Quality Assurance Policy Important Note: The Interim Exception to the Global Fund Quality Assurance Policy was expired on Decem

PSM_CoAs_List_en

Genc Kastrati — Fri, 01 Jun 2012 09:20:38 GMT

Core_GrantDetailsRaw_Report_en

Sunny Park — Fri, 01 Jun 2012 08:02:55 GMT

zzGFATMData__P_GA_D_ zzGFATMData__P_GA_D_ CompID GF Region Country CountryCd GF sub-region LFA Round_ Component_ Source ApprovedGrantAmount ApprvdBudgetStatus TotalLifetimeBudget PRName PRType GAGrantNo GASigDate ProgStartDate P1GAAmt(USDEquiv) P2GAAmt(USDEquiv) RCC1GAAmt(USDEquiv) TotalGAAmt(USDE

Core_DisbursementDetailsRaw_Report_en

Sunny Park — Fri, 01 Jun 2012 08:01:41 GMT

zzGFATMData__All_Disbursements_ zzGFATMData__All_Disbursements_Made_ GAID GFRegion CountryCd Country Round_ PRName GDDate GAGrantNo DisbNo DisbInUSD DisbInEUR Disb(USDEquiv) PRType GDID GFRating PeriodStartDate PeriodEndDate GADisease_ Sub-Saharan Africa: West & Central Africa GHN Ghana 1 Minist

Core_DisbursementDetails_Report_en

Sunny Park — Fri, 01 Jun 2012 08:01:27 GMT

Global Fund Disbursements by Region, Country and Grant Agreement (in USD equivalents) Country Grant Number Grant Amt /Principal Recipient Number Date Amount Balance Disbursements REGION: EAST ASIA & THE PACIFIC Cambodia CAM-102-G01-H-0 The Ministry of Health of the Government of the Kingdom of Cambodia Grant Amount: 14

BM01_BoardMeeting_Report_en

Genc Kastrati — Thu, 31 May 2012 16:04:57 GMT

9 – 11 rue de Varembe Mezzanine level CH -1202 Geneva Switzerland Fax +41 22 791 94 61 THE GLOBAL FUND To Fight AIDS, Tuberculosis and Malaria Interim Secretariat The Global Fund to Fight AIDS, Tuberculosis and Malaria Geneva, 28-29 January 2002 Minutes The first meeting of the Board of the Global Fund to Fight AIDS, T

TERG_TERG_ToR_en

Genc Kastrati — Tue, 29 May 2012 13:43:56 GMT

1 Technical Evaluation Reference Group for the Global Fund to fight AIDS, Tuberculosis and Malaria Terms of reference, membership and procedures April 2007 I. Background Issues: 1. As recommended in the Evaluation strategy for The Global Fund to Fight AIDS, Tuberculosis & Malaria (GFATM) (REF) and agreed by the Board i

MDAG_MarketDynamicsAdvisoryGroup_ToR_en

Genc Kastrati — Tue, 29 May 2012 13:43:39 GMT

THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA TERMS OF REFERENCE OF THE MARKET DYNAMICS ADVISORY GROUP 10 February 2012 TERMS OF REFERENCE OF THE MARKET DYNAMICS ADVISORY GROUP A. Purpose 1. The purpose of the Market Dynamics Advisory Group (MDAG) is to advise the Global Fund on policies and initiatives to im

Performance_KPI2011Results_Report_en

Genc Kastrati — Tue, 29 May 2012 11:42:08 GMT

The Global Fund 2nd Strategy, Investment and Impact Committee Meeting GF/SIIC-FOPC02/01/A Geneva, 27-28 March 2012 1/4 2nd Strategy, Investment and Impact & Finance and Operational Performance Committee Meetings Geneva, 27-28 March 2012 GF/SIIC-FOPC02/01/A For SIIC-FOPC Input KEY PERFORMANCE INDICATORS: END-YEAR RESULT

PSM_BnP0772A_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 10:50:23 GMT

PSM_BnP0152B_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 10:49:46 GMT

PSM_BnDYI422181_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 10:49:05 GMT

PSM_BnDYI392191_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 10:44:10 GMT

PSM_BnKW2185_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 05:55:46 GMT

PSM_BnKW1D19_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 05:55:15 GMT

PSM_BnFD2437_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 05:54:44 GMT

PSM_BnDYI442235_CoA_en

Krishnaswamy Raghukumar — Fri, 25 May 2012 05:54:06 GMT

Core_RenewalsInformationChartByIncome2012_Table_en

Genc Kastrati — Thu, 24 May 2012 07:49:50 GMT

Income Level Low Income Countries Lower-Low Income Countries Upper-Low Income Countries Upper-Middle Income Countries (non-G20) Upper-Middle Income Countries (G20) Disease Burden No Restrictions No Restrictions No Restrictions No Restrictions Extreme disease burden Focus of Renewal Not applicable 50% focus on special g

Core_PledgesContributions_List_en

Eric Godfrey — Wed, 23 May 2012 07:22:38 GMT

Contributions Pledges agdf Avaliable_Funds_Query Contributions_by_Value_Date Disbursement Front GFATM_Admin_Disbursement_Detail GFATM_Admin_Disbursement_Detail_1 The Global Fund to Fight AIDS, Tuberculosis and Malaria DONORS TOTAL PLEDGES TO DATE AMOUNT PLEDGED NOT YET PAID AMOUNT CONTRIBUTED Paid In To

CivilSociety_PS4RAM_CaseStudy_en

Genc Kastrati — Tue, 22 May 2012 13:07:00 GMT

Private Sector Case Study 4 – Private NGO as Principal Recipient Papua New Guinea DISEASE /INTERVENTION: Malaria LEAD ORGANIZATION INVOLVED: ROTARIANS AGAINST MALARIA GRANT DETAILS: Round 8 : Malaria Control in Papua New Guinea, Scaling up for Impact. Rotarians Against Malaria (RAM) is a co-recipient under the Dual Tra

CivilSociety_PS3AngloGoldAshanti_CaseStudy_en

Genc Kastrati — Tue, 22 May 2012 13:06:46 GMT

Private Sector Case Study 3 – Corporation as Principal Recipient Ghana DISEASE /INTERVENTION: Malaria LEAD ORGANIZATION INVOLVED: AngloGold Ashanti (Ghana) Limited GRANT DETAILS: Program Title: Accelerating Access to Prevention and Treatment of Malaria through Scaling-Up of Home-Based Care and Indoor Residual Spraying

CivilSociety_PS2ILFS_CaseStudy_en

Genc Kastrati — Tue, 22 May 2012 13:06:29 GMT

Private Sector Case Study 2 – Public Private Partnership for Health India DISEASE /INTERVENTION: HIV/AIDS LEAD ORGANIZATION INVOLVED: IL&FS Education and Technology Services Ltd. GRANT DETAILS: Round 2 Rolling Continuation Channel (RCC): Scaling up of Integrated Counseling and Testing, PPTCT and referral to Care, Suppo

CivilSociety_PS1Shell_CaseStudy_en

Genc Kastrati — Tue, 22 May 2012 13:06:10 GMT

Private Sector Case Study 1 – Public Private Partnership for Health Philippines DISEASE /INTERVENTION: Malaria LEAD ORGANIZATION INVOLVED: GRANT DETAILS: Round 5: Bolstering & Sustaining Proven & Innovative Malaria Control through Corporate-Public Partnership USD 12,968,047 (closed) Round 2 RCC (after consolidation in

CivilSociety_PS5_AtmekovFoundationForUkraine_CaseStudy_en

Genc Kastrati — Tue, 22 May 2012 13:05:38 GMT

Private Sector Case Study 5 – Foundation as Principal Recipient Ukraine DISEASE /INTERVENTION: Tuberculosis LEAD ORGANIZATION INVOLVED: Rinat Akhmetov’s Foundation for the Development of Ukraine (FDU) GRANT DETAILS: Round 9: Reducing the TB burden in Ukraine through expanding and enhancing access to high quality TB ser

PSM_BnLS120402_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 08:02:56 GMT

PSM_BnLS120401_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 08:02:25 GMT

PSM_BnLS120308_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 08:01:52 GMT

PSM_BnLS120307_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 08:01:23 GMT

PSM_BnLS120306_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 08:00:52 GMT

PSM_BnLS120305_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 08:00:16 GMT

PSM_BnLS120304_CoA_en

Krishnaswamy Raghukumar — Tue, 22 May 2012 07:59:41 GMT

PSM_BnKW2255_CoA_en

Krishnaswamy Raghukumar — Sat, 19 May 2012 07:14:17 GMT

PSM_BnFD1E53_CoA_en

Krishnaswamy Raghukumar — Sat, 19 May 2012 07:13:44 GMT

PSM_BnF2612_CoA_en

Krishnaswamy Raghukumar — Sat, 19 May 2012 07:13:07 GMT

PSM_BnDYI422127_CoA_en

Krishnaswamy Raghukumar — Sat, 19 May 2012 07:12:27 GMT

PSM_BnDYI392146_CoA_en

Krishnaswamy Raghukumar — Sat, 19 May 2012 07:11:53 GMT

Core_GovernanceHandbookVocabulary_List_en

Genc Kastrati — Fri, 18 May 2012 12:13:28 GMT

List of Commonly Used Global Fund TerminologyGovernance handbook ACT artemisinin-based combination therapy AEC Audit and Ethics Committee AMFm Affordable medicines facility -malaria ART antiretroviral therapy ARV antiretroviral BCC behavior change communications CBO community-based organization CCM Country Coordinating

Core_GovernanceHandbookSection1Overview_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:12:34 GMT

1OverviewGovernance handbookIN THIS SECTIONThis section provides information on: the creation and purpose of the Global Fund, its vision, mission and principles; the business model of the organization; a timeline of the Global Fund’s first ten years; and an overview of the Global Fund strategy for 2012–2016 as approved

Core_GovernanceHandbookSection2CoreStructures_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:12:04 GMT

2Core StructuresGovernance handbookIN THIS SECTIONThis section provides information on: the core structures which make up the Global Fund business model, with their key functions, roles and responsibilities, along with an overview of the Secretariat organizational structure.The Global Fund and Its Core StructuresAs a p

Core_GovernanceHandbookSection4GlobalFundBoard_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:11:32 GMT

4The Global Fund BoardGovernance handbookIN THIS SECTIONThis section provides information on: the structure of the Global Fund Board; its roles and responsibilities; and the key policies that govern the work of the Board and its relationship with the Secretariat.The Board’s Purpose and StructureThe Board is the supreme

Core_GovernanceHandbookSection3FundingModel_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:10:55 GMT

3Funding ModelGovernance handbookIN THIS SECTIONThis section provides information on: how countries access funding through the Global Fund; the types of funding available; the application and assessment process; what happens after Board approval and how funding is renewed; and upcoming changes in the funding model.How

Core_GovernanceHandbookSection6StandingCommittees_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:10:18 GMT

6Standing CommitteesGovernance handbookIN THIS SECTIONThis section provides information on: each of the Global Fund Board’s three standing committees; the selection process for committee members; and the specific role and responsibility of each committee in overseeing the work of the Global Fund.The Role of Committees

Core_GovernanceHandbookSection5CoordinatingGroup_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:09:44 GMT

5Coordinating GroupGovernance handbookIN THIS SECTIONThis section provides information on: the Coordinating Group of the Board; its advisory scope and its role in the overall governance structure.A New Mechanism to Improve the Governance StructureOver time, the Board Chair and Vice-Chair have needed to engage the leade

Core_GovernanceHandbookSection7BoardConstituencies_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:09:07 GMT

7Board ConstituenciesGovernance handbookIN THIS SECTIONThis section provides information on: how the Board is organized by constituency; how each constituency is formed and how constituency representatives are selected; and the working modalities and decision-making processes of constituencies.The Constituency Structur

Core_GovernanceHandbookSection8BoardOperations_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:08:28 GMT

8Board OperationsGovernance handbookIN THIS SECTIONThis section provides information on: the logistics of and attendance at Board Meetings; how the agenda is set for the work of the Board and of its committees; how Board policies are developed and decided upon; and the types of voting procedures, and how to access Boar

Core_GovernanceHandbookSection9FinancialResources_Handbook_en

Genc Kastrati — Fri, 18 May 2012 12:07:57 GMT

9FinancialResourcesGovernance handbookIN THIS SECTIONThis section provides information on: the role of the Board and its committees in financial decision-making and oversight; how the Global Fund mobilizes and manages financial resources; the role of the Trustee; how the forecasting of resources available for funding g

Corporate_TGF12024_RFP_en

Genc Kastrati — Fri, 18 May 2012 08:27:40 GMT

Corporate_TGF12022_Amendment01_en

Genc Kastrati — Wed, 16 May 2012 11:10:35 GMT

AMENDMENT No. 1 To Request for Proposals (RFP) TGF-12-022 Report Writers/Editors The purpose of this Amendment is to inform prospective offerors that the evaluation of proposals in response to the subject RFP will be conducted in 3 phases. As such 2 additional closing dates for receipt of applications are

CCM_FundingBudgetRequest_Form_en

Genc Kastrati — Mon, 14 May 2012 08:06:36 GMT

Data Definitions Assumptions and Systems CCM Funding Request Form CCM Funding Budget Instructions Country CountryList CountryRegionCCM Currency Donors FSD PerformanceArea YesNo Activity Description Unit Cost Frequency/No. of Persons Country Other Administative Costs Account holder name: Account numb

BM26_DecisionPoints_Report_en

Genc Kastrati — Fri, 11 May 2012 17:09:00 GMT

Twenty-Sixth Board Meeting Geneva, Switzerland, 10-11 May 2012 Decision Point GF/B26/DP1: Dr. Reinhard Tittel-Gronefeld from the Germany (Canada, Switzerland) constituency is designated as rapporteur for the Twenty-Sixth Board Meeting. Signed: ___________________________ Reinhard Tittel-Gronefeld Rapporteur ___________

BM26_02GeneralManagerR1_Report_en

Genc Kastrati — Fri, 11 May 2012 17:08:17 GMT

The Global Fund Twenty-Sixth Board Meeting GF/B26/02 Geneva, Switzerland, 10-11 May 2012 1/29 Twenty-Sixth Board Meeting Geneva, Switzerland, 10-11 May 2012 GF/B26/02 Board Information REPORT OF THE GENERAL MANAGER The Global Fund Twenty-Sixth Board Meeting GF/B26/02 Geneva, Switzerland, 10-11 May 2012 2/29 CONTENTS In

Core_AnnualAuditsOfFinancialStatements_Guideline_fr

Genc Kastrati — Wed, 09 May 2012 09:02:13 GMT

1 Directives relatives aux vrifications annuelles des tats financiers des rcipiendaires principaux et des sousrcipiendaires tabli le 13 aot 2010 DIRECTIVES RELATIVES AUX VRIFICATIONS ANNUELLES DES TATS FINANCIERS DES RCIPIENDAIRES PRINCIPAUX ET DES SOUS-RCIPIENDAIRES Table des matires 1. GLOSSAIRE .....................

Core_AnnualAuditsOfFinancialStatements_Guideline_es

Genc Kastrati — Wed, 09 May 2012 09:01:44 GMT

1 Directrices para realizar auditoras anuales del estado financiero de receptores principales y subreceptores Publicado el 13 de agosto de 2010 DIRECTRICES PARA REALIZAR LAS AUDITORAS ANUALES DEL ESTADO FINANCIERO DE LOS RECEPTORES PRINCIPALES Y DE LOS SUBRECEPTORES ndice 1. GLOSARIO ...................................

Core_AnnualAuditsOfFinancialStatements_Guideline_en

Genc Kastrati — Wed, 09 May 2012 09:01:27 GMT

1 Guidelines for Annual Audits of PR and SR Financial Statements Issued 13 August 2010 GUIDELINES FOR ANNUAL AUDITS OF PRINCIPAL RECIPIENTS’ AND SUB-RECIPIENTS’ FINANCIAL STATEMENTS Table of Contents 1. GLOSSARY ............................................................................................................

ME_SystemCountryProfileTool_Template_en

Genc Kastrati — Tue, 08 May 2012 11:39:03 GMT

ME_LFAGuidelinesMEProfileTool_Guidelines_en

Genc Kastrati — Tue, 08 May 2012 11:38:32 GMT

PSM_BnP1012A_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:44:41 GMT

PSM_BnKW2109_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:44:09 GMT

PSM_BnKW2036_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:43:40 GMT

PSM_BnKW2026_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:43:10 GMT

PSM_BnFD2286_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:42:37 GMT

PSM_BnFD2006_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:42:04 GMT

PSM_BnFD2003_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:41:33 GMT

PSM_BnFD1171_CoA_en

Krishnaswamy Raghukumar — Thu, 03 May 2012 15:40:59 GMT

BM25_14FinanceAndAuditCommittee_Attachment03_en

Genc Kastrati — Wed, 02 May 2012 13:36:52 GMT

Twenty-Fifth Board Meeting Accra, Ghana, 21-22 November 2011 The Global Fund Twenty-Fifth Board Meeting GF/B25/14 Attachment 3 Accra, Ghana, 21-22 November 2011 1/5 GF/B25/14 Attachment 3 For Information 2012 OPERATING EXPENSES BUDGET PURPOSE: This document sets out the 2012 budget after the incorporation of reductions

PSM_BnDYI1132017_CoA_en

Krishnaswamy Raghukumar — Tue, 01 May 2012 06:25:48 GMT

PSM_BnDYI1152095_CoA_en

Krishnaswamy Raghukumar — Tue, 01 May 2012 06:25:00 GMT

PSM_BnDYI1152066_CoA_en

Krishnaswamy Raghukumar — Tue, 01 May 2012 06:24:15 GMT

PSM_BnDYI1152022_CoA_en

Krishnaswamy Raghukumar — Tue, 01 May 2012 06:23:24 GMT

PSM_BnDYI1152020_CoA_en

Krishnaswamy Raghukumar — Tue, 01 May 2012 06:22:22 GMT

ME_PerformanceFramework_SemesterReporting

Genc Kastrati — Mon, 30 Apr 2012 08:51:36 GMT

$Meta$ $Ranges$ Translations HSS Definitions Drops Malaria TB HIV Target assumptions Performance Framework Instructions ru Instructions sp Instructions fr Instructions en Afghanistan Albania Algeria Alter_Vida___Centro_de_Estudios_y_Formaci n_para_el_Ecodesarrollo Angola Argentina Armenia Associat

ME_PerformanceFramework_QuarterlyReporting

Genc Kastrati — Mon, 30 Apr 2012 08:51:20 GMT

PSM_RDTSelection_Criteria_en

Genc Kastrati — Mon, 30 Apr 2012 08:35:18 GMT

1 Global Malaria Programme 16 September 2010 Information note on recommended selection criteria for procurement of malaria rapid diagnostic tests (RDTs) In view of the increasing demand of countries to scale up malaria diagnostics following the large-scale introduction of expensive antimalarial medicines, and the decre

ME_Part2TB_Toolkit_en

Genc Kastrati — Mon, 30 Apr 2012 08:15:39 GMT

Monitoring and Evaluation Toolkit HIV, Tuberculosis and Malaria and Health Systems Strengthening Part 2: Tools for monitoring programs for HIV, tuberculosis, malaria and health systems strengthening Tuberculosis Third Edition February 2009The M&E toolkit is available electronically at http://www.theglobalfund.org. To m

PSM_BnP0641K_CoA_en

Krishnaswamy Raghukumar — Mon, 30 Apr 2012 02:47:37 GMT

Event_LaBohemeLondon_Invite_en

Maxime Faupel — Fri, 27 Apr 2012 13:32:18 GMT

The Hackney Empire Theatre 291 Mare Street, London E8 1EJ Tuesday, 22 May 2012 Please RSVP by 7 May to: events@theglobalfund.org Private reception: 6:00pm – 7:15pm Opera: 7:30pm – 10:00pm CORDIALLY INVITES YOU TO A PERFORMANCE AND SPECIAL RECEPTION THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA LA BOHEME by IS

PSM_QADiagnostics_Malaria_list

Krishnaswamy Raghukumar — Fri, 27 Apr 2012 10:07:27 GMT

Manufacturer Product Catalogue numberProduct NameManufacturer Number of tests per kitShelf life (months)Recommended storage temperature Area of intended use-High transmission area: Panel Detection Score= at least 50%-Low & Moderate Transmission areas: Panel Detection Score =75% or more1G0141CareStart Malaria HRP2(Pf)Ac

PSM_BnSL96_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:07:17 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104532 Cli/Ref: 633-10/1309/2069 P4 GHANA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Isoniazid 300 mg Tablets Identification: SL96 Qty Rec'd: 1 SGS Sample No.: 03S11019642 Received Date: 27-Dec-2011 Procedure: DB

PSM_BnGD28013_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:06:34 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200443 Cli/Ref: 633-10/1527/2256 P5 NIGERIA Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD28013 Qty Rec'd: 1 SGS Samp

PSM_BnGD28012_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:05:49 GMT

PSM_BnGD28011_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:05:03 GMT

PSM_BnGD28010_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:04:19 GMT

PSM_BnGD28008_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:03:34 GMT

PSM_BnGD28007_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:02:51 GMT

PSM_BnGD18349_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:02:04 GMT

PSM_BnGD18348_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:01:21 GMT

PSM_BnGD18346_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 15:00:34 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200051 Cli/Ref: 633-10/1527/2256 P4 NIGERIA Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD18346 Qty Rec'd: 1 SGS Samp

PSM_BnGD18345_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:59:48 GMT

PSM_BnGD18344_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:59:02 GMT

PSM_BnGD18343_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:58:10 GMT

PSM_BnGD18342_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:57:22 GMT

PSM_BnGD18341_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:56:31 GMT

PSM_BnGC28002_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:55:39 GMT

CERTIFICATE OF ANALYSIS Client: Vera Van Den Berg Assignment No.: 04A1200155 SGS NEDERLAND BV PO No.: NA PO BOX 200 3200 AE SPIJKENISSE Page: 1 of 8 THE NETHERLANDS Product: Rifampicin 150mg/Isoniazid 75mg/Ethambutol Hydrochloride 275mg Tablets Identification: GC28002 (1 box of 24 blister sheetsx28 tablets) Product:Sto

PSM_BnGA28009_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:54:41 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200443 Cli/Ref: 633-10/1527/2256 P5 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA28009 Qty Rec'd: 2 SGS Sample No.: 03S12001513 Received Date: 06-

PSM_BnGA28008_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:53:54 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200443 Cli/Ref: 633-10/1527/2256 P5 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA28008 Qty Rec'd: 2 SGS Sample No.: 03S12001512 Received Date: 06-

PSM_BnGA28002_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:53:04 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200443 Cli/Ref: 633-10/1527/2256 P5 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA28002 Qty Rec'd: 1 SGS Sample No.: 03S12001511 Received Date: 06-

PSM_BnGA28001_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:52:08 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200443 Cli/Ref: 633-10/1527/2256 P5 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA28001 Qty Rec'd: 2 SGS Sample No.: 03S12001510 Received Date: 06-

PSM_BnGA18347_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:51:17 GMT

PSM_BnGA18200_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:50:30 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200443 Cli/Ref: 633-10/1527/2256 P5 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18200 Qty Rec'd: 1 SGS Sample No.: 03S12001509 Received Date: 06-

PSM_BnGA18196_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:49:50 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200051 Cli/Ref: 633-10/1527/2256 P4 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18196 Qty Rec'd: 1 SGS Sample No.: 03S12000199 Received Date: 09-

PSM_BnGA18195_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:49:07 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200051 Cli/Ref: 633-10/1527/2256 P4 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18195 Qty Rec'd: 1 SGS Sample No.: 03S12000198 Received Date: 09-

PSM_BnGA18194_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:48:21 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200051 Cli/Ref: 633-10/1527/2256 P4 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18194 Qty Rec'd: 1 SGS Sample No.: 03S12000197 Received Date: 09-

PSM_BnGA18193_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:47:35 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200051 Cli/Ref: 633-10/1527/2256 P4 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18193 Qty Rec'd: 1 SGS Sample No.: 03S12000196 Received Date: 09-

PSM_BnGA18192_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:46:52 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200051 Cli/Ref: 633-10/1527/2256 P4 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18192 Qty Rec'd: 1 SGS Sample No.: 03S12000195 Received Date: 09-

PSM_BnERE1103B_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:46:08 GMT

CERTIFICATE OF ANALYSIS Client: Vera Van Den Berg Assignment No.: 04A1200268 SGS NEDERLAND BV PO No.: NA PO BOX 200 3200 AE SPIJKENISSE Page: 1 of 9 THE NETHERLANDS Product: Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol Hydrochloride Tablets, IP Identification: BATCH NO:ERE1103B LABEL CLAIM:150 mg/75 mg/400 mg/27

PSM_BnERC61168A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:45:16 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: ERC61168A Qty Rec'd: 1 SGS

OIG_2012AprilReportsGMAndIGCoverNote_Note_en

Genc Kastrati — Wed, 25 Apr 2012 14:44:47 GMT

PSM_BnERC61167A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:44:35 GMT

PSM_BnERC61166A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:43:51 GMT

OIG_GFOIG11020DiagnosticReviewCuba_Report_en

Genc Kastrati — Wed, 25 Apr 2012 14:43:12 GMT

PSM_BnERC61165A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:43:04 GMT

OIG_GFOIG10014AuditEthiopia_ExecutiveSummary_en

Genc Kastrati — Wed, 25 Apr 2012 14:42:32 GMT

PSM_BnERC61164A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 14:42:19 GMT

OIG_GFOIG10011AuditKenya_ExecutiveSummary_en

Genc Kastrati — Wed, 25 Apr 2012 14:41:50 GMT

OIG_GFOIG10007AuditUzbekistan_Report_en

Genc Kastrati — Wed, 25 Apr 2012 14:41:26 GMT

OIG_GFOIG10007AuditUzbekistan_ExecutiveSummary_en

Genc Kastrati — Wed, 25 Apr 2012 14:41:06 GMT

Corporate_DEDMicrobicidesConference2012_Speech_en

Genc Kastrati — Wed, 25 Apr 2012 12:24:26 GMT

2012 International Microbicides Conference Sydney, Australia Dr Debrework Zewdie Plenary, 18 April 2012 Who pays? Global resourcing for new HIV prevention technology SLIDE 1 – TITLE SLIDE Distinguished colleagues, ladies and gentlemen -good morning. I am truly delighted to be here with you this morning. Thank you to th

Corporate_DEDMicrobicidesConference2012_Presentation_en

Genc Kastrati — Wed, 25 Apr 2012 12:23:40 GMT

Who pays? Global resourcing for new HIV prevention technology Dr Debrework Zewdie Deputy Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria Microbicides 2012 Sydney Why Microbicides? Microbicides 2012 Sydney Outline 1.Why we need microbicides 2.Research and Development 3. Funding for Roll Out 4.

Corporate_TGF12022_RFP_en

Genc Kastrati — Wed, 25 Apr 2012 12:18:43 GMT

PSM_BnERC61163A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:23:55 GMT

PSM_BnERC61162A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:22:31 GMT

PSM_BnERC61161C_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:21:28 GMT

PSM_BnERC4186A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:14:51 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4186A Qty Rec'd: 1 SGS Sample No.: 03S11019256 Received Date:

PSM_BnERC4185A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:12:52 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4185A Qty Rec'd: 1 SGS Sample No.: 03S11019255 Received Date:

PSM_BnERC4184A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:11:43 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4184A Qty Rec'd: 1 SGS Sample No.: 03S11019254 Received Date:

PSM_BnERC4183A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:10:33 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4183A Qty Rec'd: 1 SGS Sample No.: 03S11019253 Received Date:

PSM_BnERC4182A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:09:15 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4182A Qty Rec'd: 1 SGS Sample No.: 03S11019252 Received Date:

PSM_BnERC4181A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:07:31 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4181A Qty Rec'd: 1 SGS Sample No.: 03S11019251 Received Date:

PSM_BnERC4180A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:04:37 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4180A Qty Rec'd: 1 SGS Sample No.: 03S11019250 Received Date:

PSM_BnERC4179A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:03:11 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4179A Qty Rec'd: 1 SGS Sample No.: 03S11019249 Received Date:

PSM_BnERC4178A_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:02:09 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4178A Qty Rec'd: 1 SGS Sample No.: 03S11019248 Received Date:

PSM_BnERC4177E_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 10:01:04 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104474 Cli/Ref: 633-10/1316/2102 P4 BANGLADESH Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: ERC4177E Qty Rec'd: 1 SGS Sample No.: 03S11019247 Received Date:

PSM_BnCTA1045_CoA_en

Krishnaswamy Raghukumar — Wed, 25 Apr 2012 09:59:50 GMT

Malaria_WorldMalariaDay2012_Factsheet_en

Genc Kastrati — Tue, 24 Apr 2012 16:45:56 GMT

WORLD MALARIA DAY 2012 10 YEARS OF IMPACT This year, the Global Fund is celebrating 10 years of impact in fighting the three diseases in partnership with other bilateral and multilateral organizations. In its 10 years’ existence, the Global Fund has brought treatment and prevention to millions of people. The world has

Renewals_LFAPeriodicReviewBudgetReview_Checklist_en

Genc Kastrati — Tue, 24 Apr 2012 16:21:27 GMT

LFA BUDGET REVIEW CHECKLIST This checklist is to be used in conjunction with the LFA Guidelines for the Principal Recipient (PR) Assessment (Section 2.5.6), which provides instructions to LFAs in the conduct of their PR assessment work an d the LFA Budget Review Guidance Note (BRGN)

ME_Part2HIV_Toolkit_en

Genc Kastrati — Mon, 23 Apr 2012 10:36:57 GMT

Monitoring and Evaluation Toolkit HIV, Tuberculosis and Malaria and Health Systems Strengthening Part 2: Tools for monitoring programs for HIV, tuberculosis, malaria and health systems strengthening HIV Third Edition February 2009The M&E toolkit is available electronically at http://www.theglobalfund.org. To make recom

ME_MonitoringEvaluation_Toolkit_en

Genc Kastrati — Mon, 23 Apr 2012 10:36:34 GMT

Third Edition February 2009 Monitoring and Evaluation Toolkit HIV, Tuberculosis and Malaria and Health Systems Strengthening Part 1: The M&E system and Global Fund M&E requirementsThe M&E toolkit is available electronically at http://www.theglobalfund.org. To make recommendations for improving the toolkit or requests r

ME_Part2Malaria_Toolkit_en

Genc Kastrati — Mon, 23 Apr 2012 10:35:42 GMT

Monitoring and Evaluation Toolkit HIV, Tuberculosis and Malaria and Health Systems Strengthening Part 2: Tools for monitoring programs for HIV, tuberculosis, malaria and health systems strengthening Malaria Third Edition February 2009The M&E toolkit is available electronically at http://www.theglobalfund.org. To make r

ME_Part2HSS_Toolkit_en

Genc Kastrati — Mon, 23 Apr 2012 10:35:19 GMT

Monitoring and Evaluation Toolkit HIV, Tuberculosis and Malaria and Health Systems Strengthening Part 2: Tools for monitoring programs for HIV, tuberculosis, malaria and health systems strengthening Health systems strengthening Third Edition February 2009The M&E toolkit is available electronically at http://www.theglob

AMFm_DiscussionPaperMultipleCountryStakeholderConsultation_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:54:20 GMT

Affordable Medicines Facility-malaria Multi-country Stakeholder Consultation Report Submitted: September 24, 2011 Prepared by: Lloyd Matowe & Ogango K’omolo Pharmaceutical Systems Africa-www.pharmasystafrica.com 3 AMFm: MULTI-COUNTRY STAKEHOLDER CONSULTATION Table of Contents Acknowledgements .........................

AMFm_DiscussionPaperMarketAnalysesOfPublicAndPrivateSectorCapacitiesToExpandAccessToSubsidizedACTsInKenya_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:53:56 GMT

1 Project Report December 2011 BroadReach Healthcare, LLC 2500 Wilson Boulevard, Suite 220 Arlington, VA, 22201 USA Phone: +1 202 393 4515 Fax: +1 202 318 4514 Market Analysis of Public and Private Sector Capacities to Expand Access to Subsidized ACTs in Kenya 2 Development of this publication was supported by the Glob

AMFm_DiscussionPaperMarketAnalysesOfPublicAndPrivateSectorCapacitiesToExpandAccessToACTsInGhana_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:53:32 GMT

“Market Analyses of Public and Private Sector Capacities to Expand Access To Subsidized ACTs In Ghana” “My government is fully committed to public-private partnerships in health in Ghana. We believe that such arrangements often make sense and can provide expertise and capital beyond what governments alone can do. It is

AMFm_DiscussionPaperMappingDistributionAMFmCoPaidACTsNigeriaSS-SE_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:53:07 GMT

1 MAPPING CO-PAID ACTs DISTRIBUTION NETWORKS IN NIGERIA: South-South & South-East ZonesA Report on Mapping AMFm Co-paid ACTs Submitted to The Global Funds 10 September 2011 Professor AO Okhamafe (Consultant) Faculty of Pharmacy, University of Benin, Benin City Email: okhamafe@uniben.edu Tel: +234-8037269910 2 EXECUTIVE

AMFm_DiscussionPaperMappingDistributionAMFmCoPaidACTsNigeriaSW-NC_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:52:45 GMT

1 REPORT OF A PROJECT TITLED Mapping of the Distribution Networks for AMFm Co-Paid ACTs in South West and North Central Geopolitical Zones in Nigeria A = Lagos State; B = Oyo State; C= Abuja; D = Niger State A REPORT PRESENTED BY Dr Ehijie F.O. Enato, BPharm, MPharm, PhD, MPSN University of Benin (Faculty of Pharmacy)/

AMFm_DiscussionPaperMappingDistributionAMFmCoPaidACTsNigeriaNE-NW_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:52:04 GMT

1 Mapping of Co-paid ACT Distribution Networks in North-Eastern and North-Western Nigeria Affordable Medicines Facility -malaria (AMFm) Report to THE GLOBAL FUND Patrick Om Erah August, 2011 2 t, 20 11 3 Report on Mapping of Co-paid ACT Distribution Networks in North-Eastern and North-Western Nigeria Affordable Medicin

AMFm_DiscussionPaperMappingCoPaidACTsWesternKenya_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:51:41 GMT

Mapping AMFm co-paid ACT distribution networks Survey Report June – August 2011 Prepare by Tanscott Associates (T) Ltd i LIST OF ABBREVIATIONS ACTs Artemisinin Combination Therapies AMFm Affordable Medicines Facility for Malaria DHMT District Health Management Team DOMC Division of Malaria Control EMMS Essential Medici

AMFm_DiscussionPaperEffectsOfAMFmOnRetailPricesInKenya_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:51:19 GMT

Effects of AMFm on retail prices of and pricing practices for ACTs and dominant anti-malarials in Kenya Early observations under the AMFm December 2011 Investigators: L. Nneka Mobisson-Etuk and Health Action International This study was commissioned by the Global Fund to Fight AIDS Tuberculosis and Malaria. 2 Contents

AMFm_DiscussionPaperAssessmentOfTheEffectsOfTheAMFmOnMarketDynamicsOfAPIAndACTsAtTheGlobalLevel_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:50:53 GMT

1 Affordable Medicines Facility-‐malaria (AMFm): Assessment of the effects of the AMFm on market dynamics of API and ACTs at the global level Final Report January 28, 2012 January 2012 1 This report is a Working Paper to inform discussions and stimulate further analysis and exploration by interested parties. The assump

AMFm_DiscussionPaperAssessmentOfFinancialSustainabilityOfAMFm_Report_en

Genc Kastrati — Fri, 20 Apr 2012 14:50:30 GMT

Assessment of the Financial Sustainability of the Affordable Medicines Facility – malaria (AMFm) in Eight Pilot Countries (Information and Discussion Paper) Logan Brenzel, PhD Darwin Young Submitted to the AMFm Unit of The Global Fund to Fight AIDS, Tuberculosis and Malaria November 28, 2011 ii Acknowledgements We woul

ME_SelfAssessment_Checklist_es

Genc Kastrati — Fri, 20 Apr 2012 13:06:24 GMT

Phase2_StatusUpdate_List_en

Genc Kastrati — Fri, 20 Apr 2012 12:56:30 GMT

Phase 2 Board Decision Board Approved Phase 2 Funding Country, Disease, Round Grant Number(s) Date of Board Approval Additional Note on the Phase 2 Process (if any) BEN-102-G01-M-00 Conditional Go B1 BRN-102-G01-H-00 Go CHN-102-G01-T-00 A CHN-102-G02-M-00 GHN-102-G01-H-00 GHN-102-G02-T-00 HTI-102-G01-H

PSM_BnKW1A91_CoA_en

Krishnaswamy Raghukumar — Wed, 18 Apr 2012 16:14:38 GMT

PSM_BnFD2213_CoA_en

Krishnaswamy Raghukumar — Wed, 18 Apr 2012 16:13:48 GMT

LFA_OSDVDataReporting_Template_en

Genc Kastrati — Wed, 18 Apr 2012 15:43:09 GMT

SAS PHPM Summary Reporting Data Global Dashboard Summary Statistics System Assessment Summary National Level - M&E Unit Regional Site 4 Regional Site 3 Regional Site 2 Regional Site 1 District Site 8 District Site 7 District Site 6 District Site 5 District Site 4 District Site 3 District Site 2 Distr

PSM_BnF0605_CoA_en

Genc Kastrati — Wed, 18 Apr 2012 09:14:21 GMT

PSM_BnFD2158_CoA_en

Genc Kastrati — Wed, 18 Apr 2012 08:57:10 GMT

PSM_BnF0639_CoA_en

Krishnaswamy Raghukumar — Mon, 16 Apr 2012 15:24:45 GMT

PSM_BnF2565_CoA_en

Krishnaswamy Raghukumar — Mon, 16 Apr 2012 15:23:55 GMT

OIG_June2011_FraudDetectionSessionTraining_en

Maxime Faupel — Mon, 16 Apr 2012 11:30:28 GMT

Identifying, Addressing and Preventing Fraud and Financial Misappropriation Director of Investigations & Senior Legal Counsel Office of the Inspector General (OIG) 28 June 2011Fraud Detection Session Geneva, 28 June 2011 THE OFFICE OF THE INSPECTOR GENERAL

PSM_BnF2591_CoA_en

Krishnaswamy Raghukumar — Mon, 16 Apr 2012 07:38:00 GMT

PSM_BnDYI431187(N)_CoA_en

Krishnaswamy Raghukumar — Mon, 16 Apr 2012 07:31:40 GMT

PSM_BnDYI411191(N)_CoA_en

Krishnaswamy Raghukumar — Mon, 16 Apr 2012 07:30:53 GMT

PSM_BnDYI411169(N)_CoA_en

Krishnaswamy Raghukumar — Mon, 16 Apr 2012 07:30:07 GMT

PressRelease_111205_Report_fr

Genc Kastrati — Fri, 13 Apr 2012 15:40:00 GMT

Runion de haut niveau Vol et dtournement illgal de mdicaments Rapport de runion Addis-Abeba (thiopie), le 4 dcembre 2011 Contexte Le 4 dcembre 2011, le Fonds mondial, en collaboration avec le partenariat Faire reculer le paludisme, a organis Addis-Abeba (thiopie) une runion de haut niveau entre partenaires et reprsent

PressRelease_111205_Report_es

Genc Kastrati — Fri, 13 Apr 2012 15:39:36 GMT

Informe de la reunin de alto nivel sobre robo y desvo ilcito de medicamentos 4 de diciembre de 2011, Addis Abeba (Etiopa) Contexto El 4 de diciembre de 2011, el Fondo Mundial, en colaboracin con la Alianza Hacer Retroceder la Malaria, convoc una reunin de alto nivel para asociados y representantes de pases en Addis Abe

PSM_BnDYI431187N_CoA_en

Krishnaswamy Raghukumar — Fri, 13 Apr 2012 09:29:43 GMT

PSM_BnDYI411191N_CoA_en

Krishnaswamy Raghukumar — Fri, 13 Apr 2012 09:28:48 GMT

PSM_BnDYI411169N_CoA_en

Krishnaswamy Raghukumar — Fri, 13 Apr 2012 09:27:55 GMT

PSM_BnDYI411169._CoA_en

Krishnaswamy Raghukumar — Fri, 13 Apr 2012 08:59:57 GMT

GrantRenewals_2012RenewalsAnnualForecast_Table_en

Genc Kastrati — Fri, 13 Apr 2012 07:33:59 GMT

PSM_BnP0601L_CoA_en

Krishnaswamy Raghukumar — Thu, 12 Apr 2012 15:58:10 GMT

AL-BN-FD2158

Krishnaswamy Raghukumar — Thu, 12 Apr 2012 15:54:19 GMT

AL-BN-DYI431187

Krishnaswamy Raghukumar — Thu, 12 Apr 2012 15:53:19 GMT

AL-BN-DYI411191

Krishnaswamy Raghukumar — Thu, 12 Apr 2012 15:52:09 GMT

AL-BN-DYI411169

Krishnaswamy Raghukumar — Thu, 12 Apr 2012 15:50:50 GMT

Corporate_TGF12021_RFP_en

Genc Kastrati — Thu, 12 Apr 2012 15:11:31 GMT

BM25_03OIGProgress_Report_en

Genc Kastrati — Thu, 12 Apr 2012 11:23:41 GMT

THE OFFICE OF THE INSPECTOR GENERAL The Global Fund to Fight AIDS, Tuberculosis and Malaria Twenty-Fifth Board Meeting Accra, Ghana, 21-22 November 2011 The Global Fund Twenty-Fifth Board Meeting GF/B25/3, Revision 1 Accra, Ghana, 21-22 November 2011 GF/B25/3 Board Information Revision 1 THE OFFICE OF THE INSPECTOR GEN

BM24_InspectorGeneralOnTheFindingsOfTheHighLevelPanel_Comments_en

Genc Kastrati — Thu, 12 Apr 2012 11:23:19 GMT

COMMENTS BY THE INSPECTOR GENERAL ON THE FINDINGS OF THE HIGH LEVEL PANEL PRESENTED TO THE 24TH GLOBAL FUND BOARD, 26 SEPTEMBER 2011 Welcoming the Panel’s report I very much welcome the Panel’s report and its recognition of the rigor and thouroughness of the OIG’s work. The Panel concludes that the depth of the OIG’s w

GM_GlobalFundTransformationApril2012_Presentation_en

Genc Kastrati — Thu, 05 Apr 2012 07:45:09 GMT

0 Presentation by the General Manager Board Retreat: 29 March 2012 Geneva 1 Agenda •Welcome, introduction and Q&A •Strengthening the Foundations •Implementing the 2012 – 2016 strategy •Securing the resources Objectives for today Objectives •Overall plan for the fund in 2012 – 2013 •Management team •New organisational s

PSM_BnGA18173_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 17:02:11 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18173 Qty Rec'd: 1 SGS Sample No.: 03S11018403 Received Date: 05-

PSM_BnPTA1006_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 17:01:29 GMT

PSM_BnGD18311_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 17:00:59 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD18311 Qty Rec'd: 1 SGS Samp

PSM_BnGD18310_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 17:00:29 GMT

PSM_BnGD18309_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:59:59 GMT

PSM_BnGD18308_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:59:29 GMT

PSM_BnGD18307_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:59:00 GMT

PSM_BnGD18306_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:58:32 GMT

PSM_BnGD18305_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:58:03 GMT

PSM_BnGD18304_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:57:31 GMT

PSM_BnGD18303_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:57:02 GMT

PSM_BnGD18302_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:56:32 GMT

PSM_BnGD18301_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:56:04 GMT

PSM_BnGD18295_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:55:33 GMT

PSM_BnGD18294_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:55:04 GMT

PSM_BnGD18293_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:54:32 GMT

PSM_BnGD18276_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:53:59 GMT

PSM_BnGC18035_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:53:28 GMT

F110201 SGS NEDERLAND BV Attn: Mandy Reichardt MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104256 Cli/Ref: 633-10/1524/2254 P 1 NIGERIA Page: 1 of 4 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Ethambutol Hydrochloride 275mg Tablets Identification: GC18035 Qty Rec'd: 1 SGS Sample No.: 03S11018513

PSM_BnGC18034_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:52:57 GMT

PSM_BnGA18183_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:52:27 GMT

PSM_BnGA18180_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:51:57 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18180 Qty Rec'd: 1 SGS Sample No.: 03S11018408 Received Date: 05-

PSM_BnGA18179_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:51:28 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18179 Qty Rec'd: 1 SGS Sample No.: 03S11018407 Received Date: 05-

PSM_BnGA18176_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:50:52 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18176 Qty Rec'd: 1 SGS Sample No.: 03S11018406 Received Date: 05-

PSM_BnGA18170_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:49:41 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18170 Qty Rec'd: 1 SGS Sample No.: 03S11018401 Received Date: 05-

PSM_BnGA18175_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:16:12 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18175 Qty Rec'd: 1 SGS Sample No.: 03S11018405 Received Date: 05-

PSM_BnGA18174_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:15:29 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18174 Qty Rec'd: 1 SGS Sample No.: 03S11018404 Received Date: 05-

PSM_BnGA18172_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:14:27 GMT

PSM_BnGA18171_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 16:13:53 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18171 Qty Rec'd: 1 SGS Sample No.: 03S11018402 Received Date: 05-

PSM_BnGA18169_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 14:54:57 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18169 Qty Rec'd: 1 SGS Sample No.: 03S11018400 Received Date: 05-

PSM_BnGA18155_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 14:51:59 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1104227 Cli/Ref: 633-10/1527/2256 P3 NIGERIA Page: 1 of 2 CERTIFICATE OF ANALYSIS Product: Rifampicin 150 mg/Isoniazid 75 mg tablets Identification: GA18155 Qty Rec'd: 1 SGS Sample No.: 03S11018399 Received Date: 05-

PSM_BnERD2123A_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 14:51:27 GMT

PSM_BnCC1330_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 14:50:57 GMT

PSM_BnCC1328_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 14:50:24 GMT

PSM_BnCA4282_CoA_en

Krishnaswamy Raghukumar — Mon, 02 Apr 2012 14:49:44 GMT

PSM_VPPKeyResultsMarch2012_Report_en

Genc Kastrati — Wed, 28 Mar 2012 15:14:09 GMT

28th March 2012 VPP KEY RESULTS (2009 — 2011) Voluntary Pooled Procurement (VPP) became operational in mid-2009. It is a short-term strategy aimed at ensuring a cost effective and efficient procurement of core health products: ARVs, ACTs, LLINs, and rapid diagnostic tests (RDTs) for HIV and malaria1. PARTICIPATION: KEY

AMFm_Phase1IndependentEvaluationMultiCountryBaseline_Report_en

Genc Kastrati — Wed, 28 Mar 2012 13:50:40 GMT

Multi-Country Baseline Report Independent Evaluation of the Affordable Medicines Facility -malaria (AMFm) Phase 1 March 22, 2012 Independent Evaluation of Phase 1 of the Affordable Medicines Facility -malaria (AMFm) Multi-Country Baseline Report March 22, 2012 Independent Evaluator team ICF Macro: London School of Hygi

GM_GeneralManagerElMundo2012March_Interview_en

Genc Kastrati — Wed, 28 Mar 2012 12:39:56 GMT

'It is difficult to find investments that give a return higher than those made in health' El Mundo 03/26/2012 Just seven weeks have passed since Gabriel Jaramillo, former Chief Executive of Sovereign Bank, took over as General Manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the transformation of

AMFm_PriceTrackingByHAIJanuary2012Survey_Report_en

Genc Kastrati — Tue, 27 Mar 2012 14:32:32 GMT

1 Retail prices of ACTs co-paid by the AMFm and other antimalarial medicines: Ghana, Kenya, Madagascar, Nigeria, Tanzania and Uganda Report of price tracking surveys Survey Date: January 2012 Investigators: Health Action International (www.haiweb.org and www.haiafrica.org) These price tracking studies were commissioned

PSM_BnX11454_CoA_en

Krishnaswamy Raghukumar — Tue, 27 Mar 2012 08:35:59 GMT

PSM_BnP0161L_CoA_en

Krishnaswamy Raghukumar — Tue, 27 Mar 2012 08:35:32 GMT

PSM_BnP0171L_CoA_en

Krishnaswamy Raghukumar — Tue, 27 Mar 2012 08:35:01 GMT

PSM_BnD12324_CoA_en

Krishnaswamy Raghukumar — Tue, 27 Mar 2012 08:34:28 GMT

Corporate_TGF12020_RFI_en

Genc Kastrati — Thu, 22 Mar 2012 14:47:15 GMT

ME_DataQuality_Module_en

Genc Kastrati — Thu, 22 Mar 2012 13:34:36 GMT

PSM_BnDYI431187_CoA_en

Krishnaswamy Raghukumar — Thu, 22 Mar 2012 08:18:48 GMT

PSM_BnDYI411191_CoA_en

Krishnaswamy Raghukumar — Thu, 22 Mar 2012 08:18:20 GMT

PSM_BnDYI411169_CoA_en

Krishnaswamy Raghukumar — Thu, 22 Mar 2012 08:17:55 GMT

PSM_Bn5422_CoA_en

Krishnaswamy Raghukumar — Thu, 22 Mar 2012 08:17:27 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200741 Cli/Ref: 632-02/2012/01/S P2, SANOFI Page: 1 of 4 CERTIFICATE OF ANALYSIS Product: Artesunate 100 mg/Amodiaquine 270 mg Tablets Identification: 5422 Qty Rec'd: 25 SGS Sample No.: 03S12002596 Received Date: 29

PSM_Bn1080_CoA_en

Krishnaswamy Raghukumar — Thu, 22 Mar 2012 08:16:56 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200741 Cli/Ref: 632-02/2012/01/S P2, SANOFI Page: 1 of 3 CERTIFICATE OF ANALYSIS Product: Artesunate 25 mg/Amodiaquine 67.5 mg Tablets Identification: 1080 Qty Rec'd: 50 SGS Sample No.: 03S12002597 Received Date: 29

CCM_MeetingMinutesExcel_Template_en

Genc Kastrati — Tue, 20 Mar 2012 16:10:27 GMT

Drop down values Instructions Attendance Sheet Attendance Sheet CCM Minutes template Abstention Against Agenda_items Agenda_items Agenda_items Agreed Annexes Annexes Annexes Annexes_attached CCM_Name CCM_role Checklist CountriesList Country Country Country CountryCodesList Decision_making Decisio

PSM_BnG18445_CoA_en

Krishnaswamy Raghukumar — Tue, 20 Mar 2012 11:31:42 GMT

N/Ref: 03A1200806 Cli/Ref: 632/2011-050 CAMBODIA, CIPLA Page: 1 of 5 CERTIFICATE OF ANALYSIS F110201 SGS NEDERLAND BV Attn: Geert Geerligs MALLEDIJK 18 3200 AE SPIJKENISSE NL Product: Artesunate and Mefloquine Hydrochloride tablets 50/250mg Identification: G18445 (adults) Qty Rec'd: 1 SGS Sample No.: 03S12002795 Receiv

PSM_BnG18508_CoA_en

Krishnaswamy Raghukumar — Tue, 20 Mar 2012 11:31:12 GMT

N/Ref: 03A1200805 Cli/Ref: 632/2010-145 CAMBODIA, CIPLA Page: 1 of 5 CERTIFICATE OF ANALYSIS F110201 SGS NEDERLAND BV Attn: Geert Geerligs MALLEDIJK 18 3200 AE SPIJKENISSE NL Product: Artesunate and Mefloquine Hydrochloride tablets 50/250mg Identification: G18508 (adults) Qty Rec'd: 1 SGS Sample No.: 03S12002794 Receiv

PSM_BnG18454_CoA_en

Krishnaswamy Raghukumar — Tue, 20 Mar 2012 11:30:41 GMT

N/Ref: 03A1200806 Cli/Ref: 632/2011-050 CAMBODIA, CIPLA Page: 1 of 5 CERTIFICATE OF ANALYSIS F110201 SGS NEDERLAND BV Attn: Geert Geerligs MALLEDIJK 18 3200 AE SPIJKENISSE NL Product: Artesunate and Mefloquine Hydrochloride tablets 50/250mg Identification: G18454 (adults) Qty Rec'd: 1 SGS Sample No.: 03S12002796 Receiv

Corporate_TGF12003_RFP_en

Genc Kastrati — Tue, 20 Mar 2012 11:00:38 GMT

OIG_GFOIG11009InvestigationMauritania_Report_en

Genc Kastrati — Tue, 20 Mar 2012 10:55:43 GMT

THE OFFICE OF THE INSPECTOR GENERAL The Global Fund to Fight AIDS, Tuberculosis and Malaria FINAL REPORT OF INVESTIGATION OF MAURITANIA MALARIA (2 & 6) AND TUBERCULOSIS (2 & 6) AND HIV/AIDS (5) GRANTS AND A CASE STUDY ON THE ROLE OF THE SECRETARIAT, THE LOCAL FUND AGENT, THE COUNTRY COORDINATING MECHANISM, and UNDP IN

OIG_GFOIG11009InvestigationMauritania_Summary_en

Genc Kastrati — Tue, 20 Mar 2012 10:55:27 GMT

1/10 THE OFFICE OF THE INSPECTOR GENERAL The Global Fund to Fight AIDS, Tuberculosis and Malaria EXECUTIVE SUMMARY FINAL REPORT OF INVESTIGATION OF MAURITANIA MALARIA (2 & 6) AND TUBERCULOSIS (2 & 6) AND HIV/AIDS (5) GRANTS AND A CASE STUDY ON THE ROLE OF THE SECRETARIAT, THE LOCAL FUND AGENT, THE COUNTRY COORDINATING

CCM_ExpandedFundingBudgetRequest_Form_en

Genc Kastrati — Mon, 19 Mar 2012 13:27:39 GMT

ReportData Data Assumptions and Systems Budget-Summary WorkPlan Co-Payment Detailed budget Y2 Detailed budget Y1 Performance Framework CCM Funding Request Form Instructions Menu AgreementNumber AreaAbbreviation AreaIndicator AreaPerAbreviation CCM CCMPerCountry CostCategory_FullNameByAbv CostCategory

CCM_MeetingMinutes_Template_en

Genc Kastrati — Thu, 15 Mar 2012 17:39:11 GMT

PSM_QCLab_List_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:40:25 GMT

List Disclaimer to the List of Quality Control Laboratories: 2. A QC lab that is not equipped to undertake microbiological testing (sterility test, bacterial endotoxin test and microbial count) can be used, provided the laboratory will undertake the responsibility to perform the microbiological tests in another QC la

PSM_BnGD18363_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:39:27 GMT

F110201 SGS NEDERLAND BV Attn: Mandy Reichardt MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200400 Cli/Ref: 623/7702-0 SO P1 INDONESIA Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD18363 Qty Rec'd: 1 SGS Sample No.: 03S1

PSM_BnGD18364_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:39:03 GMT

PSM_BnGD18365_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:38:38 GMT

PSM_BnGD28001_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:38:11 GMT

PSM_BnGD28002_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:37:45 GMT

F110201 SGS NEDERLAND BV Attn: Mandy Reichardt MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200398 Cli/Ref: 623/7702-0 SO P2 INDONESIA Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD28002 Qty Rec'd: 1 SGS Sample No.: 03S1

PSM_BnGD28003_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:37:19 GMT

PSM_BnGD28009_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:36:49 GMT

F110201 SGS NEDERLAND BV Attn: Vera van den Berg -Kahlman MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1200507 Cli/Ref: 623/7702-0 P1 INDONESIA Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD28009 Qty Rec'd: 1 SGS Sample N

PSM_BnGD18277_CoA_en

Krishnaswamy Raghukumar — Thu, 15 Mar 2012 10:36:23 GMT

F110201 SGS NEDERLAND BV Attn: Mandy Reichardt MALLEDIJK 18 3200 AE SPIJKENISSE NL N/Ref: 03A1103793 Cli/Ref: 633-10/1343/2104 P2 MOZAMBIQUE Page: 1 of 5 CERTIFICATE OF ANALYSIS Product: Rifampicin 150mg/Isoniazid 75mg/Pyrazinamide 400mg/Ethambutol HCl 275mg Tablets Identification: GD18277 Qty Rec'd: 1 SGS Sample No.: